Mirum CEO exercises options, sells 30K shares
Mirum Pharmaceuticals, Inc. director and chief executive officer Christopher Peetz reported option exercises and share sales in the company’s stock.
Rhea-AI Filing Summary
Mirum Pharmaceuticals, Inc. director and chief executive officer Christopher Peetz reported option exercises and share sales in the company’s stock. On June 1, 2026, he exercised stock options for 30,000 shares of common stock at an exercise price of $2.936 per share and sold 30,000 shares of common stock in multiple open-market transactions. The sales occurred at prices ranging from about $93.90 to $99.79 per share pursuant to a pre-arranged Rule 10b5-1 Plan adopted on March 2, 2026. Following these transactions, he holds 194,309 shares of common stock directly and 187,500 shares indirectly through The Peetz Family Trust, as well as 128,487 stock options outstanding.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 30,000 shares ($2.79M approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
Peetz Christopher
Role
CHIEF EXECUTIVE OFFICER
Sold
30,000 shs ($2.88M)
Approx. gross sale proceeds
$2.88M
Approx. exercise cost
$88K
Approx. pre-tax spread
$2.79M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 30,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 30,000 | $2.936 | $88K |
| Sale | Common Stock | 2,602 | $94.64 | $246K |
| Sale | Common Stock | 16,595 | $95.34 | $1.58M |
| Sale | Common Stock | 6,926 | $96.15 | $666K |
| Sale | Common Stock | 1,973 | $97.56 | $192K |
| Sale | Common Stock | 1,021 | $98.20 | $100K |
| Sale | Common Stock | 883 | $99.66 | $88K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 128,487 contracts (Direct);
Common Stock — 194,309 shares (Direct);
Common Stock — 187,500 shares (Indirect, By The Peetz Family Trust)
Footnotes (8)
- F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026.
- F2. The weighted average sale price for the transaction reported was $94.64, and the range of prices were between $93.90 and $94.895. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F3. The weighted average sale price for the transaction reported was $95.34, and the range of prices were between $94.91 and $95.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F4. The weighted average sale price for the transaction reported was $96.15, and the range of prices were between $95.92 and $96.8675. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F5. The weighted average sale price for the transaction reported was $97.56, and the range of prices were between $96.98 and $97.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F6. The weighted average sale price for the transaction reported was $98.20, and the range of prices were between $98.00 and $98.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F7. The weighted average sale price for the transaction reported was $99.66, and the range of prices were between $99.55 and $99.79. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F8. The stock option is fully vested.
Key Figures
Shares sold: 30,000 shares
Sale price range: $93.90–$99.79 per share
Options exercised: 30,000 shares
+5 more
8 metrics
Shares sold
30,000 shares
Total common stock sold in open-market transactions on June 1, 2026
Sale price range
$93.90–$99.79 per share
Price ranges from weighted-average sale footnotes
Options exercised
30,000 shares
Employee stock options converted into common stock on June 1, 2026
Option exercise price
$2.936 per share
Exercise price for employee stock options
Direct common shares after
224,309 shares
Direct Mirum common stock holding following reported transactions
Indirect trust shares
187,500 shares
Common stock held indirectly via The Peetz Family Trust
Remaining stock options
128,487 options
Employee stock options outstanding after the exercise
Rule 10b5-1 plan adoption date
March 2, 2026
Date the CEO adopted the trading plan governing these sales
Key Terms
Rule 10b5-1 Plan, weighted average sale price, Employee Stock Option (right to buy), open-market sale, +1 more
5 terms
Rule 10b5-1 Plan regulatory
"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average sale price financial
"The weighted average sale price for the transaction reported was $94.64, and the range of prices were between $93.90 and $94.895."
Employee Stock Option (right to buy) financial
"security_title: Employee Stock Option (right to buy)"
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action: derivative exercise/conversion"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Mirum Pharmaceuticals (MIRM) CEO Christopher Peetz report in this Form 4?
Christopher Peetz reported exercising stock options for 30,000 Mirum Pharmaceuticals shares and selling 30,000 shares in open-market transactions. The filing also updates his direct, indirect, and option holdings following these June 1, 2026 transactions.
What stock options did the Mirum Pharmaceuticals (MIRM) CEO exercise?
He exercised employee stock options covering 30,000 Mirum Pharmaceuticals common shares at an exercise price of $2.936 per share. After this exercise, the table shows 128,487 stock options remaining outstanding in his direct derivative holdings.
What is the indirect Mirum Pharmaceuticals (MIRM) holding reported for The Peetz Family Trust?
The filing lists an indirect ownership entry of 187,500 Mirum Pharmaceuticals common shares held by The Peetz Family Trust. This reflects shares attributed to Christopher Peetz through the trust, separate from his directly held common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
